Multidomain efficacy and safety of IL-17A and IL-17A/F inhibitors versus adalimumab in biologic-naïve psoriatic arthritis: A systematic review and Meta-analysis of comparative trials
Multidomain efficacy and safety of IL-17A and IL-17A/F inhibitors versus adalimumab in biologic-naïve psoriatic arthritis: A systematic review and Meta-analysis of comparative trials. // Autoimmunity Reviews. – URL: https://www.sciencedirect.com/science/article/pii/S1568997226002442?dgcid=rss_sd_all
Multidomain efficacy and safety of IL-17A and IL-17A/F inhibitors versus adalimumab in biologic-naïve psoriatic arthritis: A systematic review and Meta-analysis of comparative trials. Autoimmunity Reviews. https://www.sciencedirect.com/science/article/pii/S1568997226002442?dgcid=rss_sd_all
“Multidomain efficacy and safety of IL-17A and IL-17A/F inhibitors versus adalimumab in biologic-naïve psoriatic arthritis: A systematic review and Meta-analysis of comparative trials.” Autoimmunity Reviews.
@article{article411,
title = {Multidomain efficacy and safety of IL-17A and IL-17A/F inhibitors versus adalimumab in biologic-naïve psoriatic arthritis: A systematic review and Meta-analysis of comparative trials},
journal = {Autoimmunity Reviews},
url = {https://www.sciencedirect.com/science/article/pii/S1568997226002442?dgcid=rss_sd_all}
}